Spectral Medical Delays FDA Filing for Breakthrough Sepsis Device

TORONTO, ON – February 26, 2026 – Spectral Medical Inc., a company developing a novel treatment for septic shock, announced today a revised timeline for its U.S. regulatory submission, a move it says will strengthen its application for a potentially life-saving device.

The Toronto-based theranostic company now plans to submit its Premarket Approval (PMA) application for the PMX-20R hemoadsorption device to the U.S. Food and Drug Administration (FDA) between late April and mid-May 2026. This marks a shift from its original target of the first quarter of 2026. The company stated the adjustment follows recent interactions with the FDA, aimed at creating a more comprehensive and robust data package.

A Strategic Pivot for a Stronger Submission

The primary reason for the updated timeline is the inclusion of complete 12-month mortality data from the company's pivotal Tigris clinical trial. According to Spectral, this decision stems from ongoing feedback with the FDA. The submission will also incorporate the completion of several non-clinical components, including human factors engineering tests, to ensure the application is fully compliant and prepared for a thorough review.

While any delay in a regulatory timeline can be viewed with caution, Spectral is framing the move as a strategic effort to enhance the quality of its submission and facilitate a more efficient review process.

“We continue to work constructively with the FDA to ensure a high-quality PMA submission,” said Chris Seto, Chief Executive Officer of Spectral Medical, in the company's press release. “The inclusion of longer-term mortality data and completion of the remaining non-clinical components are intended to support a comprehensive submission and will position PMX for an efficient review process.”

The PMA pathway is the FDA's most stringent regulatory process for medical devices, reserved for high-risk Class III products that sustain or support human life. Approval requires extensive evidence of safety and effectiveness, and companies often engage in detailed discussions with the agency to ensure their data package meets the high bar for approval. By proactively including longer-term outcomes, Spectral aims to provide the totality of evidence needed for a device targeting a life-threatening condition.

The High Stakes of Sepsis and the Promise of PMX

The device at the center of the submission, known as Toraymyxin™ or PMX, targets endotoxic septic shock, a malignant form of sepsis with a high mortality rate. Sepsis is a leading cause of death in hospitals, and in North America alone, approximately 330,000 patients are diagnosed with septic shock each year. Despite its prevalence, there are currently no specific therapies approved in the United States that target endotoxin, a key trigger in this deadly cascade.

PMX is a therapeutic hemoperfusion device that works by filtering a patient's blood outside the body to remove endotoxin. What makes Spectral’s approach unique is its "theranostic" model. The use of PMX is guided by the company's FDA-cleared Endotoxin Activity Assay (EAA™), a diagnostic test that measures the level of endotoxin in a patient's blood. This allows clinicians to identify patients most likely to benefit from the therapy, representing a significant step towards personalized medicine in the intensive care unit.

The potential of PMX has already been recognized by the FDA, which granted it Breakthrough Device Designation in July 2022. This designation is intended to expedite the development and review of devices that could provide more effective treatment for life-threatening diseases. Furthermore, the device is not entirely new to the global stage; it is already approved for use in Japan and Europe and is licensed in Canada, with over 360,000 units sold worldwide to date, providing a substantial real-world record of its safety profile.

Decoding the Tigris Trial Data

The foundation of Spectral's PMA submission is the Tigris trial, a confirmatory Phase 3 study involving 150 patients randomized to receive either PMX with standard care or standard care alone. The trial utilized a sophisticated Bayesian statistical model, a method increasingly accepted by the FDA for medical device trials as it allows for the incorporation of prior data to make studies more efficient.

In August 2025, Spectral announced that the Tigris study had successfully met its primary endpoint. The trial demonstrated a posterior probability of benefit of 95.3% for 28-day mortality, surpassing the prespecified success threshold of 95%. The observed 28-day mortality was 38.7% in the PMX group compared to 45.1% in the control group.

However, subsequent data has suggested the benefits of the therapy may become even more pronounced over time. Data for 90-day mortality showed a striking 17.4% absolute difference in survival, with a mortality rate of 43.4% for PMX patients versus 60.8% for the control group. This longer-term benefit is what the company now seeks to formalize in its submission with the inclusion of 12-month data, which it expects to report in late May or early June 2026.

According to one renowned expert in blood purification for sepsis, the longer follow-up period is critical. "For critically ill patients, 28-day survival can sometimes be a prelude to a prolonged and difficult hospital stay. Seeing a survival benefit that not only holds but widens at 90 days and beyond is far more indicative of a truly meaningful therapeutic impact," the expert noted. This perspective aligns with the company's decision to bolster its application with the 12-month outcomes.

Navigating the Regulatory Gauntlet and Investor Scrutiny

The decision to delay the submission, while strategically sound, places Spectral under the market's microscope. The company's stock saw a minor dip of just over 2% following the announcement. However, many analysts remain optimistic, with some one-year price targets projecting significant upside, reflecting confidence in the device's eventual approval and commercial potential.

This optimism is balanced against the financial realities of a pre-commercial medtech company. While Spectral's revenue from existing product sales grew to $2.29 million in 2024, the company continues to operate at a loss as it invests heavily in research, development, and the regulatory process. The delay modestly extends the period of cash burn before potential U.S. revenue can be realized.

Ultimately, the short-term delay is being weighed against the long-term prize: tapping into the significant unmet medical need for a septic shock therapy in the lucrative U.S. market. By taking additional time to assemble a more comprehensive data package, Spectral Medical is betting that a stronger, more complete application will pave the smoothest possible path through the FDA's rigorous review and toward the patients who desperately need new treatment options.